Axsome Therapeutics, Inc. (NASDAQ ... This article provides a comprehensive analysis of Axsome's current position, future prospects, and potential challenges in the competitive CNS drug market.

Axsome Therapeutics (AXSM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...

Ratings for Axsome Therapeutics AXSM were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

Investors in Axsome Therapeutics Inc (Symbol: AXSM) saw new options become available this week, for the September 19th expiration. One of the key data points that goes into the price an option ...

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth ... In conclusion, Axsome Therapeutics presents a compelling investment case with its strong commercial ...

Beyond AXS-05 and AUVELITY, Axsome has a robust pipeline that could drive future growth. AXS-07 for acute migraine ... In conclusion, Axsome Therapeutics presents a compelling investment case with its ...